Bookmark and Share
isoquercitrin (CID 5280804) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(56)
 
 
Inactive(319)
 
 
Inconclusive(9)
 
 
Unspecified(118)
 
 
Top Targets:
alkPPc(19)
 
 
 
7TM GPCR Srx(12)
 
 
 
Bcl-2 like(9)
 
 
7TM GPCR Srsx(7)
 
 
 
NR LBD PPAR(7)
 
 
 
BioAssay Types:
Screening(189)
 
 
 
 
Literature(188)
 
 
 
 
 
Confirmatory(109)
 
 
 
 
BioActivity Types:
Potency(58)
 
 
 
 
IC50(56)
 
 
 
 
EC50(10)
 
 
 
Ki(1)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 470    Data Row: 502   Total Pages: 11   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103557565]
ED50 1.2Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR [AID638568, Type: Literature]
View
2
[SID49681636]
IC50_Mean 1.66Dose Response confirmation of uHTS hits from a small molecule inhibitors of mouse intestinal alkaline phosphatase via a luminescent assay [AID488785, Type: confirmatory]intestinal alkaline phosphatase precursor [Mus musculus] [gi:124487323]
View
3
[SID26719900]
Potency 1.7783qHTS Assay for Inhibitors of DNA Polymerase Beta [AID485314, Type: confirmatory]DNA polymerase beta [Homo sapiens] [gi:4505931]
View
4
[SID103557565]
IC50 3Inhibition of human recombinant aldose reductase using D-glyceraldehyde as substrate preincubated for 10 mins before substrate addition measured for every 10 secs for 50 mins by spectrophotometry [AID639825, Type: Literature]Aldose reductase [gi:113596]
View
5
[SID26719900]
Potency 3.5481qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen [AID2100, Type: confirmatory]lysosomal alpha-glucosidase preproprotein [Homo sapiens] [gi:119393891]
View
6
[SID103557565]
IC50 4.4Inhibition of Sprague-Dawley rat lens aldose reductase [AID654333, Type: Literature]Aldose reductase [gi:1168407]
View
7
[SID49681636]
IC50_Mean 5.25Dose Response confirmation of uHTS hits from a small molecule inhibitors of human intestinal alkaline phosphatase via a luminescent assay [AID463135, Type: confirmatory]Alkaline phosphatase, intestinal [Homo sapiens] [gi:124376142]
View
8
[SID26719900]
Potency 8.9125qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a [AID504332, Type: confirmatory]euchromatic histone-lysine N-methyltransferase 2 [Homo sapiens] [gi:168985070]
View
9
[SID49681636]
IC50_Mean 8.96Dose Response confirmation of uHTS inhibitors of Mouse Intestinal Alkaline Phosphatase using Human Intestinal Alkaline Phosphatase [AID488876, Type: confirmatory]Alkaline phosphatase, intestinal [Homo sapiens] [gi:124376142]
View
10
[SID103557565]
IC50 9.2Inhibition of advanced glycation end-products formation after 14 days by spectrofluorimetry [AID654332, Type: Literature]
View
11
[SID103557565]
IC50 11.7Antioxidant activity assessed as DPPH radical scavenging activity after 10 mins [AID597947, Type: Literature]
View
12
[SID26719900]
Potency 12.5893qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E) [AID2147, Type: confirmatory]Chain A, Crystal Structure Of The Human 2-Oxoglutarate Oxygenase Loc390245 [gi:221046486]
View
13
[SID49681636]
IC50_Mean 14Dose Response confirmation of uHTS inhibitors of Mouse Intestinal Alkaline Phosphatase using Tissue Nonspecific Alkaline Phosphatase. [AID488906, Type: confirmatory]alkaline phosphatase, tissue-nonspecific isozyme isoform 1 precursor [Homo sapiens] [gi:116734717]
View
14
[SID49681636]
EC50_uM 15.8Luminescence Cell-Free Homogeneous Dose Retest to Identify Inhibitors of Glycogen Synthase Kinase-3 beta Activity [AID434954, Type: confirmatory]glycogen synthase kinase-3 beta isoform 1 [Homo sapiens] [gi:21361340]
View
15
[SID103557565]
IC50 16Inhibition of pig lens aldose reductase by spectrophotometry [AID354608, Type: Literature]Aldose reductase [gi:584742]
View
16
[SID103557565]
IC50 17.9Antioxidant activity assessed as DPPH radical scavenging activity [AID721289, Type: Literature]
View
17
[SID103557565]
IC50 19.8Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method [AID717568, Type: Literature]
View
18
[SID103557565]
IC50 32.2Antioxidant activity assessed as DPPH free radical scavenging activity [AID356427, Type: Literature]
View
19
[SID103557565]
IC50 33.6Inhibition of TNF-alpha-induced NFkappaB activation in human HEK293 cells after 6 hrs by luciferase reporter gene assay [AID587224, Type: Literature]
View
20
[SID103557565]
Inhibition of AMPK-mediated adipocyte differentiation in mouse 3T3L1 cells [AID517389, Type: Literature]
View
21
[SID103557565]
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as nitrite level at 1 to 100 uM after 24 hrs by Griess method [AID578570, Type: Literature]
View
22
[SID103557565]
Antioxidant activity assessed as DPPH free radical scavenging activity at 2 ug by TLC autographic assay [AID380836, Type: Literature]
View
23
[SID103557565]
Antioxidant activity assessed as DPPH free radical scavenging activity at 4 ug by TLC autographic assay [AID380837, Type: Literature]
View
24
[SID103557565]
Antioxidant activity assessed as DPPH free radical scavenging activity at 6 ug by TLC autographic assay [AID380838, Type: Literature]
View
25
[SID103557565]
Antioxidant activity assessed as DPPH free radical scavenging activity at 8 ug by TLC autographic assay [AID380839, Type: Literature]
View
26
[SID103557565]
Antiproliferative activity against human HL60 cells at 30 uM after 48 hrs by MTS assay [AID381804, Type: Literature]
View
27
[SID103557565]
Hepatoprotective activity against HBV in human HepG2.2.15 cells [AID311973, Type: Literature]
View
28
[SID103557565]
Antiviral activity against hepatitis B virus assessed as inhibition of viral particle production [AID311974, Type: Literature]
View
29
[SID103557565]
Drug level in human plasma [AID317348, Type: Literature]
View
30
[SID103557565]
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as suppression of plaque formation at 40 ug/ml by plaque-reduction assay [AID336602, Type: Literature]
View
31
[SID103557565]
Antagonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay [AID311281, Type: Literature]Mu-type opioid receptor [gi:2851402]
View
32
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced COX2 mRNA expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by RT-PCR [AID687528, Type: Literature]
View
33
[SID103557565]
Cytotoxicity against MDCK cells after 4 days [AID638569, Type: Literature]
View
34
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced COX2 protein expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western blot [AID687506, Type: Literature]
View
35
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced iNOS mRNA expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by RT-PCR [AID687507, Type: Literature]
View
36
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced iNOS protein expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western blot [AID687508, Type: Literature]
View
37
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced TNFalpha production at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by ELISA [AID687509, Type: Literature]
View
38
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as increase in CCL-induced nuclear Nrf2 protein level at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western blot [AID687510, Type: Literature]
View
39
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as augmentation of CCL-induced HO-1 mRNA expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by RT-PCR [AID687511, Type: Literature]
View
40
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as augmentation of CCL-induced HO-1 protein expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western blot [AID687512, Type: Literature]
View
41
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in Kupffer cell hyperplasia at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by hematoxylin-eosin staining based method [AID687513, Type: Literature]
View
42
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in portal inflammation at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by hematoxylin-eosin staining based method [AID687514, Type: Literature]
View
43
[SID103557565]
Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in centrizonal necrosis at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by hematoxylin-eosin staining based method [AID687515, Type: Literature]
View
44
[SID103557565]
Inhibition of PPAR-gamma-mediated adipocyte differentiation in mouse 3T3L1 cells [AID517390, Type: Literature]Peroxisome proliferator-activated receptor gamma [gi:13432235]
View
45
[SID26719900]
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays [AID1217, Type: screening]Dihydrolipoamide dehydrogenase [Homo sapiens] [gi:17391426]
View
46
[SID26719900]
IC50 HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay. [AID1209, Type: confirmatory]MPI protein [Homo sapiens] [gi:16878311]
View
47
[SID85787971]
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity [AID651548, Type: screening]histone-lysine N-methyltransferase EZH2 isoform a [Homo sapiens] [gi:21361095]
View
48
[SID26719900]
QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP). [AID1822, Type: screening]M18 aspartyl aminopeptidase [Plasmodium falciparum 3D7] [gi:23505220]
View
49
[SID49681636]
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format. [AID485346, Type: screening]protein Mdm4 isoform 1 [Homo sapiens] [gi:88702791]
View
50
[SID49681636]
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format. [AID485346, Type: screening]E3 ubiquitin-protein ligase Mdm2 isoform a [Homo sapiens] [gi:89993689]
View